GlassScriptPhysician profile
Kevin Cottle
NPI 1245440478
$2,053.00
in general payments reported to CMS, 2019-2025
29 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $550 · 2022: $612 · 2023: $442 · 2024: $298 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $616.18 | 2021-2025 | |
| Lilly USA, LLC | $399.18 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $110.30 | 2021-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $102.89 | 2023-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Glaxosmithkline, LLC. | $90.20 | 2021-2023 | Arexvy, Shingrix |
| Tris Pharma INC | $85.17 | 2023-2024 | Dyanavel Xr |
| Boston Scientific Corporation | $66.71 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $47.25 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.11 | 2021 | |
| Alkermes, INC. | $40.98 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $40.21 | 2022-2023 | Quviviq |
| Corium, LLC | $39.03 | 2023-2024 | Azstarys |
| Mannkind Corporation | $38.09 | 2021 | |
| Neurelis, INC. | $31.05 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $30.49 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $26.50 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.69 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.52 | 2022 | |
| Eisai INC. | $23.05 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.33 | 2022 | |
| Medtronic, INC. | $22.09 | 2024 | Intellis Adaptivestim |
| Hologic Sales and Service, LLC | $18.47 | 2023 | Aptima |
| Dexcom, INC. | $18.29 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.81 | 2025 | Caplyta |
| Abbott Laboratories | $16.45 | 2021 | |
| Sanofi Pasteur INC. | $15.41 | 2023 | |
| Apria Healthcare LLC | $15.29 | 2021 | |
| Seqirus USA INC | $14.07 | 2022 | |
| Cranial Technologies, INC | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Cottle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.